A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02392234 |
|
Recruitment Status :
Completed
First Posted : March 18, 2015
Results First Posted : June 12, 2018
Last Update Posted : June 12, 2018
|
Sponsor:
Vertex Pharmaceuticals Incorporated
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of VX-661 in combination with ivacaftor (IVA, VX-770) and IVA monotherapy in participants with Cystic Fibrosis (CF) who are heterozygous for F508del-CFTR allele and a second allele with a CFTR mutation predicted to have residual function.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cystic Fibrosis | Drug: VX-661/Ivacaftor Drug: Ivacaftor Drug: Placebo matched to VX-661/ ivacaftor Drug: Placebo matched to Ivacaftor | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 248 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function |
| Study Start Date : | March 2015 |
| Actual Primary Completion Date : | February 2017 |
| Actual Study Completion Date : | February 2017 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Cystic fibrosis
MedlinePlus related topics:
Cystic Fibrosis
Drug Information available for:
Ivacaftor
| Arm | Intervention/treatment |
|---|---|
| Experimental: VX-661/Ivacaftor combination |
Drug: VX-661/Ivacaftor
Fixed dose combination tablet, oral use
Other Name: VX-661+VX-770 Drug: Ivacaftor Tablet, oral use
Other Name: IVA, VX-770 Drug: Placebo matched to Ivacaftor Tablet, oral use |
| Experimental: Ivacaftor monotherapy |
Drug: Ivacaftor
Tablet, oral use
Other Name: IVA, VX-770 Drug: Placebo matched to VX-661/ ivacaftor Fixed dose combination tablet, oral use |
| Placebo Comparator: Placebo |
Drug: Placebo matched to VX-661/ ivacaftor
Fixed dose combination tablet, oral use Drug: Placebo matched to Ivacaftor Tablet, oral use |
Primary Outcome Measures :
- Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Week 4 and Week 8 [ Time Frame: Baseline, Week 4 and Week 8 of each treatment period ]FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Secondary Outcome Measures :
- Absolute Change From Study Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Week 4 and Week 8 [ Time Frame: Baseline, Week 4 and Week 8 of each treatment period ]The CFQ-R assessed respiratory symptoms on a scale with scores ranging from 0 to 100; where higher scores indicated fewer symptoms and better health-related quality of life.
- Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Day 1 up to Week 28 ]
- Relative Change From Study Baseline in ppFEV1 at Average of Week 4 and Week 8 [ Time Frame: Baseline, Week 4 and Week 8 of each treatment period ]FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
- Absolute Change From Study Baseline in Sweat Chloride at Average of Week 4 and Week 8 [ Time Frame: Baseline, Week 4 and Week 8 of each treatment period ]
- Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1 VX-661), IVA and IVA Metabolite (M1 IVA) After Administration of VX-661/IVA Combination Therapy [ Time Frame: Pre-morning dose on Week 8 of each treatment period ]
- Ctrough of IVA and IVA Metabolite (M1 IVA) After Administration of IVA Monotherapy [ Time Frame: Pre-morning dose on Week 8 of each treatment period ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 12 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Heterozygous for F508del-CFTR and a second allele with a CFTR mutation predicted to have residual function
- Forced Expiratory Volume in 1 Second (FEV1) greater than or equal to (≥) 40 percent (%) and less than or equal to (≤) 90% of predicted normal for age, sex, and height during screening
- Sweat chloride value ≥60 millimole per liter (mmol/L) during screening OR as documented in the participant's medical record
- Stable CF disease as judged by the investigator
Exclusion Criteria:
- History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant
- An acute upper or lower respiratory infection, pulmonary exacerbation
- History of solid organ or hematological transplantation
- Ongoing or prior participation in an investigational drug study (including studies investigating VX-661, lumacaftor [VX-809], and/or ivacaftor) within 30 days of screening
- Pregnant and nursing females
- Sexually active participants of reproductive potential who are not willing to follow the contraception requirements
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02392234
Locations
Show 94 study locations
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
Study Documents (Full-Text)
Documents provided by Vertex Pharmaceuticals Incorporated:
Documents provided by Vertex Pharmaceuticals Incorporated:
Study Protocol [PDF] June 10, 2016
Statistical Analysis Plan [PDF] February 24, 2017
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Vertex Pharmaceuticals Incorporated |
| ClinicalTrials.gov Identifier: | NCT02392234 |
| Other Study ID Numbers: |
VX14-661-108 2014-004788-18 ( EudraCT Number ) |
| First Posted: | March 18, 2015 Key Record Dates |
| Results First Posted: | June 12, 2018 |
| Last Update Posted: | June 12, 2018 |
| Last Verified: | May 2018 |
Additional relevant MeSH terms:
|
Cystic Fibrosis Fibrosis Pathologic Processes Pancreatic Diseases Digestive System Diseases Lung Diseases Respiratory Tract Diseases |
Genetic Diseases, Inborn Infant, Newborn, Diseases Ivacaftor Chloride Channel Agonists Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |